Sara M. Tolaney, MD, MPH

An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive, HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.

An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.

An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.

An expert from Dana-Farber Cancer Institute discusses what the approval of sacituzumab govitecan means for patients with advanced hormone receptor–positive, HER2-negative breast cancer.

Closing out their review of the HER2+ metastatic breast cancer treatment landscape, expert oncologists look forward to future evolutions in the paradigm.

Panelists center their discussion on the challenges inherent in managing leptomeningeal metastases in patients with HER2+ breast cancer.

Experts share brief insights on novel agents in development for HER2+ breast cancer and consider how they may impact the treatment landscape.

Centering discussion on trastuzumab deruxtecan use in HER2+ metastatic breast cancer, experts elucidate adverse event management and concurrent radiation therapy.

A brief review on how best to use MRI following CNS-directed radiation therapy in patients with HER2+ metastatic breast cancer.

Following review of the final patient scenario, panelists consider later-line treatment options in the setting of multiply relapsed HER2+ metastatic breast cancer.

Comprehensive review of novel combination treatment strategies being explored for patients with HER2+ breast cancer and brain metastases.

Panelists reflect on sequencing therapy for HER2+ metastatic breast cancer following disease progression on the tucatinib, trastuzumab and capecitabine regimen.

A panel of expert oncologists highlight the use of the tucatinib, trastuzumab and capecitabine regimen that was investigated in the HER2CLIMB trial to manage patients with HER2+ breast cancer and brain metastases.

Expert perspectives on the respective role of radiation therapy to manage brain metastases in the setting of HER2+ breast cancer.

Paolo Tarantino, MD, and Sara M. Tolaney, MD, MPH, spoke with CancerNetwork® about highlights from 2022 ASCO in breast cancer research.

This video examines an early trial studying abemaciclib for the treatment of brain metastases in patients with hormone receptor–positive, HER2-negative breast cancer.

This video highlights 7-year follow-up data from the APT trial, which studied adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

This video examines the idea of using clinical features (age, tumor size) to reduce treatment burden in patients with HER2-positive breast cancer.

This video examines chemotherapy options for HER2-positive breast cancer in the adjuvant setting, and what evidence there is for alternatives to an anthracycline backbone.